TMG / betaine
Preclinical · 4 studies cited · 2 min · Updated 2026-08-14
In short: No trial of betaine (trimethylglycine) has ever measured a joint outcome — not thin evidence, zero. What exists: solid human data that betaine lowers homocysteine, genetic epidemiology tying homocysteine modestly to OA risk, and recent rodent studies where betaine protected cartilage and subchondral bone. Textbook preclinical.
Betaine is a methyl donor: it remethylates homocysteine to methionine, lowering plasma homocysteine and supporting S-adenosylmethionine production. Two hypothesised joint links follow. First, elevated homocysteine may impair collagen cross-linking, and genetics associates it with modestly higher OA risk. Second — and more recently — betaine acts as an osmolyte and, in rodent work, suppresses ROS/MAPK-driven osteoclastogenesis in the subchondral bone beneath cartilage. Plausible, and entirely unproven in human joints.
The human evidence, such as it is
No trial of betaine/TMG has ever measured a joint, cartilage, or connective-tissue outcome. What exists is indirect:
A meta-analysis of 5 RCTs found betaine (typically 4–6 g/day) lowers plasma homocysteine by a pooled 1.23 µmol/L. Real, modest, and a surrogate.
A Mendelian randomization study found genetically higher homocysteine associated with slightly higher overall OA risk (OR ~1.10) and folate apparently protective. That supports the pathway betaine acts on — but the measured protective exposures were folate and B12, not betaine, the effect sizes are small, and pleiotropy is hard to exclude.
The animal data — better than expected, still animal
In mice with surgically induced knee OA, betaine reduced cartilage proteoglycan loss and OARSI histology scores, decreased MMP-13 and collagen-X-positive cells, and normalised subchondral bone remodelling and aberrant angiogenesis. In a rat temporomandibular-joint OA model, betaine enhanced chondrogenic differentiation of stem cells and betaine-treated cells improved cartilage repair — note that this is a cell-therapy adjunct, not oral supplementation. The theme (redox and remodelling modulation) is consistent, but these come from single groups, with doses and group sizes not stated in abstracts, and no independent replication.
Dosing & practical notes
No joint-outcome dose exists, because no joint outcome has been measured. Homocysteine trials used roughly 3–6 g/day; the sports-performance literature typically uses 2.5 g/day. If you take TMG, the only honest framing is "methylation and homocysteine support, with speculative joint upside." Nothing here justifies taking it for cartilage.
Contradicting evidence & limitations
Nothing clinical can be contradicted because nothing clinical has been tested — that absence is itself the headline limitation. One documented adverse surrogate cuts against casual high-dose use: at 4 g/day and above, betaine can raise LDL and total cholesterol. Whether homocysteine lowering per se changes OA incidence is an open factorial question the folate/B12 literature has not answered either.
Safety
Well tolerated at 3–6 g/day in homocysteine trials. The main flags are the dose-dependent cholesterol increases above and a fishy body odour (trimethylamine) some users get. Prescription betaine has long-term safety data in homocystinuria at much higher doses. No known joint-relevant drug interactions.
What I take from it
The rodent cartilage data turned out somewhat better than expected going into this review — and nothing about that changes the category. Until someone takes oral betaine into a human trial with a joint endpoint (none is registered), this is a mechanism with a supplement attached, not a joint therapy.
Why this tier? Human joint evidence is zero: betaine's human trials measure homocysteine (a surrogate, pooled -1.23 µmol/L across 5 RCTs), and the joint-relevant efficacy comes from single-group rodent OA models without independent replication. A Mendelian randomization study supports the pathway (OR ~1.10 for homocysteine on OA), not the supplement.